Co-Diagnostics (NASDAQ:CODX) vs. DocGo (NASDAQ:DCGO) Head to Head Contrast

Co-Diagnostics (NASDAQ:CODX) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Co-Diagnostics and DocGo, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	0	1	1	1	3.00
DocGo	0	3	3	0	2.50

Co-Diagnostics presently has a consensus target price of $5.50, suggesting a potential upside of 1,675.34%. DocGo has a consensus target price of $3.59, suggesting a potential upside of 127.22%. Given Co-Diagnostics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Co-Diagnostics is more favorable than DocGo.

Institutional & Insider Ownership

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 6.1% of Co-Diagnostics shares are owned by company insiders. Comparatively, 3.8% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Co-Diagnostics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, DocGo has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares Co-Diagnostics and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-3,588.33%	-69.49%	-60.49%
DocGo	-4.20%	-3.26%	-2.24%

Valuation and Earnings

This table compares Co-Diagnostics and DocGo”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$3.91 million	3.05	-$37.64 million	($1.15)	-0.27
DocGo	$616.55 million	0.25	$19.99 million	($0.19)	-8.32

DocGo has higher revenue and earnings than Co-Diagnostics. DocGo is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

DocGo beats Co-Diagnostics on 9 of the 15 factors compared between the two stocks.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.